During February 2025, Revvity proudly stands at the forefront of newborn screening, leading the charge in recognizing and addressing rare diseases that impact countless lives around the world.
Rare diseases, often overlooked, affect a significant portion of the global population. Revvity's dedication to newborn screening is a testament to our commitment to early detection and intervention, paving the way for improved outcomes and quality of life.
Rare diseases, also known as orphan diseases, are conditions that affect a small percentage of the population. In various regions, a disease is typically considered rare when it afflicts fewer than 1 in 2,000 individuals. However, the exact prevalence thresholds may vary from one country to another.
What makes rare diseases particularly challenging is the diversity and complexity of these conditions. There are thousands of identified rare diseases, each with its own unique set of symptoms and characteristics. Many of these conditions are genetic in nature, resulting from mutations or alterations in an individual's DNA.
Due to their infrequency, rare diseases often pose significant diagnostic and therapeutic challenges. Misdiagnosis or delays in diagnosis are not uncommon, leading to prolonged periods of uncertainty for affected individuals and their families. This highlights the crucial role of early detection and intervention, a mission that Revvity wholeheartedly embraces.
While individual rare diseases may affect only a small number of people, collectively, they impact millions worldwide. This makes raising awareness and fostering understanding of rare diseases vital for ensuring that those affected receive the attention and support they need.
Revvity's commitment to newborn screening plays a pivotal role in the early identification of these conditions. By employing advanced screening technologies, healthcare professionals can detect markers and indicators associated with various rare diseases shortly after birth, enabling timely interventions and personalized treatment plans.
We believe that newborn screening should be available for everyone.
Petra Furu, General Manager of Revvity’s reproductive health business, reflects on the past few years and looks to the future and comments:
"I am proud yet humbled by Revvity's dedication to improving newborn screening worldwide.
Revvity is continually developing new technologies to meet the demands of newborn screening today and for the future. Through our research, collaborations, and partnerships we are helping to decipher the role of next generation sequencing in newborn screening, both in terms of testing and in the delivery of digital solutions and data management. Revvity has recently partnered with the European collaborative Screen4Care, with several key initiatives to be deployed through 2025."
This month, we celebrate the resilience of those facing rare diseases and emphasize the importance of awareness. Our continuously advancing technologies and screening solutions contribute to enhancing patient care, helping to ensure that rare diseases are detected and addressed.
As a global leader in the newborn screening market, Revvity understands the critical role we play in identifying these conditions at the earliest stages. Our newborn screening systems and solutions enable healthcare professionals to make early, informed decisions, offering hope and support to families navigating the challenges of rare diseases.
Revvity's unwavering dedication extends beyond technology. We actively collaborate with healthcare communities, advocacy groups, and researchers to foster a holistic approach to rare disease management. By fostering awareness, we contribute to a global effort to transform the landscape for those affected by these conditions.
This February, join us in recognizing the strength and resilience of individuals and families impacted by rare diseases. Through our collective efforts, we can raise awareness, promote early detection, and ultimately make strides towards a brighter, healthier future for all.
Rare Disease Awareness Day is February 28. Revvity remains steadfast in its mission to advance science and improve lives. Together, let's make a difference in the lives of those touched by rare diseases, today and every day.
Revvity, Inc. does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.
